QGEN
Qiagen N.V.
NYSEUSDEQUITY
DELAYED
Last price
44.07
▼ 0.83 (1.85%)
MARKET · —
Price
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
44.49
Prev close
44.90
Day high
44.47
Day low
43.78
Volume
2.90M
Market cap
—
P/E (TTM)
—
52W range
32.53 – 57.82
Trailing performance
Returnvs SPY
1W
+2.61%
+4.0%
1M
+6.32%
+2.6%
3M
+26.31%
+23.2%
6M
-9.26%
-20.3%
YTD
-2.00%
-14.3%
1Y
-10.43%
-30.4%
3Y
-1.17%
-75.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on QGEN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.09B | $1.98B | $1.97B | $2.14B | +5.7% |
| Operating revenue | $2.09B | $1.98B | $1.97B | $2.14B | +5.7% |
| Cost of revenue | $790.50M | $1.01B | $731.62M | $756.96M | -21.8% |
| Gross profit | $1.30B | $967.35M | $1.23B | $1.38B | +34.3% |
| Research & development | $187.52M | $193.49M | $198.51M | $189.86M | -3.1% |
| Selling, general & admin | $583.67M | $564.36M | $579.17M | $603.95M | +3.4% |
| Total operating expense | $779.18M | $767.45M | $788.44M | $808.34M | +1.5% |
| Operating income | $520.31M | $199.90M | $445.25M | $576.23M | +160.3% |
| Net interest income | $31.06M | $24.18M | $25.58M | -$25.60M | +28.5% |
| Pre-tax income | $490.26M | $121.15M | $429.81M | $512.60M | +304.7% |
| Tax provision | $65.39M | $37.56M | $88.51M | $89.39M | +74.1% |
| Net income | $424.88M | $83.59M | $341.30M | $423.21M | +408.3% |
| Net income to common | $424.88M | $83.59M | $341.30M | $423.21M | +408.3% |
| Basic EPS | 2.06 | 0.42 | 1.67 | 2.08 | +386.4% |
| Diluted EPS | 2.04 | 0.41 | 1.65 | 2.05 | +394.5% |
| EBIT | $523.52M | $164.99M | $483.22M | $570.96M | +217.3% |
| EBITDA | $717.27M | $368.26M | $688.55M | $779.36M | +94.8% |
| Basic shares | 206.36M | 199.44M | 204.40M | 203.89M | +3.5% |
| Diluted shares | 207.94M | 201.32M | 206.61M | 206.18M | +3.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $839.00M | $663.55M | $668.08M | $730.67M | — | +26.4% |
| Cash & short-term investments | $1.10B | $1.15B | $1.06B | $1.42B | — | -4.7% |
| Accounts receivable | $402.61M | $349.28M | $381.88M | $323.75M | — | +15.3% |
| Inventory | $301.89M | $279.26M | $398.38M | $357.96M | — | +8.1% |
| Total current assets | $2.00B | $1.96B | $2.15B | $2.39B | — | +1.8% |
| Property, plant & equipment | $1.08B | $753.61M | $765.04M | $662.17M | — | +42.9% |
| Goodwill & intangibles | $3.09B | $2.73B | $3.00B | $2.90B | — | +13.1% |
| Total assets | $6.28B | $5.69B | $6.12B | $6.29B | — | +10.4% |
| Total current liabilities | $512.14M | $1.04B | $1.08B | $974.52M | — | -50.9% |
| Current debt | — | $551.88M | $587.97M | $389.55M | $847.63M | — |
| Long-term debt | $1.65B | $839.66M | $921.82M | $1.47B | — | +97.0% |
| Total debt | $1.81B | $1.51B | $1.53B | $1.88B | — | +19.8% |
| Total liabilities | $2.50B | $2.12B | $2.31B | $2.82B | — | +17.9% |
| Retained earnings | $2.75B | $2.45B | $2.46B | $2.16B | — | +12.3% |
| Shareholder equity | $3.78B | $3.57B | $3.81B | $3.47B | — | +5.9% |
| Working capital | $1.48B | $917.82M | $1.07B | $1.42B | — | +61.6% |
| Net tangible assets | $691.07M | $838.11M | $805.21M | $569.25M | — | -17.5% |
| Shares issued | 206.80M | 206.80M | 206.80M | 206.80M | — | +0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $424.88M | $83.59M | $341.30M | $423.21M | — | +408.3% |
| Depreciation & amortisation | $193.75M | $203.27M | $205.34M | $208.40M | — | -4.7% |
| Stock-based compensation | $50.40M | $43.63M | $47.10M | $49.51M | — | +15.5% |
| Change in working capital | -$34.51M | $135.45M | -$186.96M | -$31.88M | — | -125.5% |
| Operating cash flow | $654.33M | $673.55M | $459.45M | $715.26M | — | -2.9% |
| Capital expenditure | -$207.13M | -$171.24M | -$162.80M | -$149.34M | — | -21.0% |
| Investing cash flow | -$305.28M | -$249.23M | -$87.66M | -$726.76M | — | -22.5% |
| Share buybacks | — | -$292.10M | $0 | $0 | -$99.99M | — |
| Dividends paid | -$54.24M | $0 | $0 | — | — | — |
| Financing cash flow | -$178.98M | -$422.90M | -$433.83M | -$125.80M | — | +57.7% |
| Free cash flow | $447.20M | $502.31M | $296.65M | $565.93M | — | -11.0% |
| End cash position | $839.00M | $663.55M | $668.08M | $730.67M | — | +26.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $535.04M | $492.32M | $540.42M | $532.58M | $533.54M | +8.7% |
| Operating revenue | $535.04M | $492.32M | $597.72M | $514.91M | $533.54M | +8.7% |
| Cost of revenue | $194.65M | $182.72M | $215.15M | $201.32M | $199.25M | +6.5% |
| Gross profit | $340.39M | $309.60M | $325.27M | $331.26M | $334.29M | +9.9% |
| Research & development | $50.43M | $48.26M | $47.23M | $48.75M | $47.75M | +4.5% |
| Selling, general & admin | $146.77M | $142.39M | $153.88M | $143.11M | $148.75M | +3.1% |
| Total operating expense | $199.54M | — | — | — | — | — |
| Operating income | $140.85M | $116.63M | $121.88M | $137.29M | $135.97M | +20.8% |
| Net interest income | -$661.00K | -$489.00K | $9.86M | $6.85M | $6.25M | -35.2% |
| Pre-tax income | $132.10M | $85.83M | $109.17M | $134.73M | $126.82M | +53.9% |
| Tax provision | $28.70M | $17.79M | $1.34M | $4.68M | $30.57M | +61.4% |
| Net income | $103.40M | $68.04M | $107.83M | $130.04M | $96.25M | +52.0% |
| Net income to common | $103.40M | $68.04M | $107.83M | $130.04M | $96.25M | +52.0% |
| Basic EPS | 0.50 | 0.33 | 0.52 | 0.63 | 0.46 | +51.5% |
| Diluted EPS | 0.50 | 0.33 | 0.52 | 0.63 | 0.46 | +51.5% |
| EBIT | $142.13M | $96.88M | $119.31M | $142.94M | $134.43M | +46.7% |
| EBITDA | $192.68M | $148.09M | $168.70M | $193.91M | $183.90M | +30.1% |
| Basic shares | 206.35M | 207.01M | 206.07M | 206.03M | 205.87M | -0.3% |
| Diluted shares | 207.83M | 208.94M | 207.76M | 207.53M | 207.27M | -0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $768.50M | $646.29M | $839.00M | $1.36B | $733.82M | — | +18.9% |
| Cash & short-term investments | $793.50M | $646.29M | $1.10B | $1.69B | $953.82M | — | +22.8% |
| Accounts receivable | $389.85M | $396.62M | $402.61M | $375.56M | $385.76M | — | -1.7% |
| Inventory | $311.36M | $309.61M | $301.89M | $290.23M | $292.55M | — | +0.6% |
| Total current assets | $1.66B | $1.54B | $2.00B | $2.53B | $1.82B | — | +7.6% |
| Property, plant & equipment | $923.04M | $914.79M | $1.08B | $897.64M | $874.95M | — | +0.9% |
| Goodwill & intangibles | $3.05B | $3.06B | $3.09B | $2.85B | $2.87B | — | -0.6% |
| Total assets | $5.89B | $5.78B | $6.28B | $6.55B | $5.82B | — | +1.9% |
| Total current liabilities | $581.45M | $479.11M | $512.14M | $973.40M | $1.13B | — | +21.4% |
| Current debt | $16.52M | — | — | $499.60M | $559.19M | $55.69M | — |
| Long-term debt | $1.63B | $1.65B | $1.65B | $1.63B | $884.85M | — | -1.2% |
| Total debt | $1.64B | $1.65B | $1.81B | $2.13B | $1.44B | — | -0.2% |
| Total liabilities | $2.53B | $2.45B | $2.50B | $2.90B | $2.32B | — | +3.3% |
| Retained earnings | $2.81B | $2.80B | $2.75B | $2.65B | $2.52B | — | +0.5% |
| Shareholder equity | $3.36B | $3.33B | $3.78B | $3.65B | $3.51B | — | +0.8% |
| Working capital | $1.08B | $1.06B | $1.48B | $1.56B | $690.67M | — | +1.3% |
| Net tangible assets | $312.00M | $268.24M | $691.07M | $797.76M | $639.26M | — | +16.3% |
| Shares issued | 206.50M | 206.80M | 206.80M | 206.80M | 206.80M | — | -0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $103.40M | $68.04M | $107.83M | $130.04M | $96.25M | +52.0% |
| Depreciation & amortisation | $50.55M | $51.21M | $49.39M | $50.97M | $49.48M | -1.3% |
| Stock-based compensation | $6.97M | $9.65M | $16.59M | $10.71M | $10.76M | -27.8% |
| Change in working capital | $38.93M | -$42.14M | $10.64M | -$26.42M | -$4.13M | +192.4% |
| Operating cash flow | $200.69M | $100.63M | $188.13M | $165.02M | $161.44M | +99.4% |
| Capital expenditure | -$43.37M | -$48.48M | -$71.58M | -$50.45M | -$40.84M | +10.6% |
| Investing cash flow | -$70.26M | $211.47M | -$226.47M | -$156.90M | -$42.00M | -133.2% |
| Share buybacks | — | — | — | $0 | — | — |
| Dividends paid | — | — | $1.00K | — | — | — |
| Financing cash flow | -$8.47M | -$503.66M | -$478.35M | $614.07M | -$27.99M | +98.3% |
| Free cash flow | $157.32M | $52.15M | $116.55M | $114.57M | $120.60M | +201.7% |
| End cash position | $768.50M | $646.29M | $839.00M | $1.36B | $733.82M | +18.9% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
43.41
+1.53% from price
SMA 20
42.64
+3.36% from price
SMA 50
40.69
+8.32% from price
SMA 100
38.85
+13.43% from price
SMA 200
42.76
+3.06% from price
EMA 12
43.27
+1.85% from price
EMA 26
42.33
+4.12% from price
EMA 50
41.17
+7.04% from price
RSI (14)
61.0
Neutral
MACD (12,26,9)
0.94
Hist 0.08
ATR (14)
1.22
2.77% of price
Realised vol 30D
25.8%
Annualised
Bollinger upper
44.66
20, 2σ
Bollinger lower
40.61
20, 2σ
50 / 200 cross
Death
40.69 vs 42.76
Trend bias
Above 200
+3.06%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.34
Less volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
25.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-41.4%
Peak to trough
Max drawdown 5Y
-44.4%
Peak to trough
ATR 14
1.22
2.77% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?
Zacks · 3d ago
4% Undervalued? Qiagen (QGEN) As Q2 Beat And FDA Clearance Lift The Story
Simply Wall St. · 9d ago
Qiagen (QGEN) Beat Its Own Guidance, So Why Did Margins Slip?
Insider Monkey · 9d ago
Strong Beats Mask Zillow’s (Z) Restructuring And Headwinds
Insider Monkey · 9d ago
Will FDA Clearance of QIAstat-Dx Bloodstream Panel Change Qiagen's (QGEN) Syndromic Testing Narrative?
Simply Wall St. · 10d ago
Qiagen (QGEN) Q2 2026 Earnings Call Transcript
Motley Fool · 10d ago
QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel
Business Wire · 12d ago
Understanding Qiagen (QGEN) Reliance on International Revenue
Zacks · 13d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.